Human Pinealectomy Syndrome and the Impact of Melatonin Replacement Therapy: 1-Cardiovascular Function.

No hypertension was observed in melatonin-deficient pinealectomized patients at baseline.

• Study comprised 11 patients aged 16.7 ± 1.7 years who had undergone pinealectomy with no tumor recurrence
• All patients exhibited undetectable salivary melatonin levels
• Patients were described as 'normotensive' despite being melatonin-deficient
• Ambulatory blood pressure monitoring was used to assess cardiovascular status

Diastolic blood pressure progressively decreased over the 6-month melatonin replacement therapy, reaching statistical significance at 6 months.

• Melatonin regimen was 0.3 mg daily for 6 months
• Ambulatory blood pressure monitoring was conducted at baseline, 3-month, and 6-month intervals
• The decrease in diastolic blood pressure was progressive but did not reach statistical significance at the 3-month assessment
• Statistical significance was achieved at the 6-month interval

Pulse pressure exhibited a gradual increase during melatonin replacement therapy, reaching statistical significance after 6 months.

• Pulse pressure increase was gradual across the study period
• Statistical significance was reached at the 6-month mark
• The increase in pulse pressure alongside decreased diastolic blood pressure was interpreted as consistent with improved cardiovascular health
• The study used a prospective open-label, single-arm proof-of-concept design

Short-term blood pressure variability increased significantly for both systolic and diastolic pressures following melatonin replacement therapy.

• Both systolic and diastolic short-term blood pressure variability were significantly increased
• Enhanced short-term blood pressure variability was interpreted as consistent with improved cardiovascular health
• The authors suggest this may reflect heightened reactivity during wakefulness

Morning systolic and diastolic blood pressure levels were significantly decreased by melatonin replacement therapy.

• Morning blood pressure reductions were observed for both systolic and diastolic measurements
• The authors suggest melatonin's temporal specificity might enhance nighttime recovery
• This effect suggests melatonin may heighten reactivity during wakefulness
• A dose of 0.3 mg daily was used, described as a replacement rather than pharmacological dose

Melatonin replacement therapy had no effect on average heart rate or heart rate variability.

• Neither average heart rate nor its variability was significantly altered over the 6-month treatment period
• This was assessed at baseline, 3-month, and 6-month intervals via ambulatory monitoring
• The cardiovascular effects of melatonin appeared selective to blood pressure parameters rather than heart rate